Pharmacological targeting of missense TP53 mutations has traditionally failed owing to the mutant heterogeneity, gain-of-function oncogenic properties and paradoxical stability of mutant p53 protein. A ‘p53-conditional’ proximity strategy promises to eradicate TP53 missense mutant-driven cancer by exploiting its abundance.
